Moleculin Q1 2022 Earnings Report
Key Takeaways
Moleculin Biotech reported its Q1 2022 financial results, highlighting progress across its pipeline, including advancements in clinical and regulatory strategies, particularly outside the U.S. The company's development programs for Annamycin and WP1122 continue to advance. They ended the quarter with $66.1 million in cash and believe they have enough to fund operations into 2024.
Received authorizations for a Phase 1a clinical trial of WP1122 in the UK for COVID-19 treatment.
Engaged Wolfram C. M. Dempke as European Chief Medical Officer for European clinical trials.
Received IND clearance to conduct a Phase 1 study of WP1066 for recurrent malignant glioma.
Annamycin exhibited antitumor activity in experimental colorectal cancer liver and lung metastasis models, as presented at AACR 2022.
Moleculin
Moleculin
Forward Guidance
Moleculin Biotech anticipates several key clinical and regulatory milestones throughout 2022, with sufficient capital to fund operations into 2024. They expect to provide more clarity for each clinical program’s path towards registration, and address unmet needs for people with highly resistant tumors and viruses.
Positive Outlook
- Commence Phase 1/2 study in Europe for AML evaluating Annamycin + Ara-C (Q2 2022).
- Commencement of an investigator-funded Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases in Europe (Q2 2022).
- Report topline data from Phase 1b portion of ongoing Phase 1b/2 study of Annamycin for sarcoma lung metastases in the US (Q2 2022).
- Commence recruitment in Phase 1a study of WP1122 for COVID-19 in the UK (Q2 2022).
- Potential to launch Phase 2 study of WP1122 for COVID-19 outside of the US (H2 2022).